Skip to main content
Program
#AHA25
Late-Breaking Science
Daily Coverage
Industry Highlights
Photo Gallery
Journeys
Late-Breaking Science
LBS 01: Celebrating a century of cardiovascular science
Intensive blood pressure control, tirzepatide and novel gene editing therapy.
LBS 08: Advances in lipid therapeutics
LBS 07: New approaches to managing AFib
LBS 06: Medical therapy for heart failure
LBS 05: Innovation in prevention
Save the date for #AHA25 in New Orleans
LBS 04: Coronary and valvular heart disease
Liberal or restrictive oxygenation, GLP-1 agonist therapy, edoxaban and spironolactone.
Sponsored
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Earn credit and learn from expert faculty during this free symposium on thromboembolic disease designed to encourage the exchange of ideas between leaders in the field and attendees.
LBS 03: Harnessing AI for better heart health
Improving guideline-directed medical therapy, comparing wearable versus implanted sensors, boosting echocardiogram performance and automating echocardiographic interpretation.
LBS 02: Redefining arrhythmia treatment
Catheter ablation, OPTION and Brain-AF.
Clinical Guideline Sessions
Get up to speed on all of the updates in guidelines.
Late-Breaking Science for Sunday
Two presentations feature results from intervention and prevention studies.
Featured Science for Saturday
Check out these featured studies.
Don't miss today's Main Events
Six powerful Main Events to kick off your Scientific Sessions 2024.
Cutting-edge science highlights #AHA24
#AHA24 has slated presentation of 29 Late-Breaking Science results and 29 Featured Science studies during the meeting.
#AHA24 Late-Breaking and Featured Science announced
See the impressive lineup of science planned for presentation at Scientific Sessions 2024.
Late-breaking science| Achieving equity in prevention
Novel mechanisms for lipid-lowering therapy
Late-breaking science: AI at the bedside
Shocking decisions in AFib care
Drugs, diet and delivery can optimize hypertension outcomes
Heart failure late-breaking science
Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes
Trials’ results suggest new approaches to reducing CVD risk and symptoms
Late-Breaking Science announced
Early ablation bests medication in treatment naïve AFib patients
First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
